| Literature DB >> 23842073 |
Sergio Davinelli1, Nadia Sapere, Manuela Visentin, Davide Zella, Giovanni Scapagnini.
Abstract
Emerging evidence suggests that combinatorial action of numerous biologically active compounds may be a valuable source in a variety of therapeutic applications. Several nutraceuticals have demonstrated to augment the efficacy of pharmacological approaches or provide physiological benefit to improve age-related decline. Recently, the possibilities of anti-ageing interventions have multiplied also to ameliorate the mitochondrial alterations in ageing-associated diseases. In this report, we approached a novel treatment strategy by combining two bioactive dietary constituents (resveratrol and equol) to determine their effect on mitochondrial function. Taking into account that the biological activities of resveratrol and equol has been observed in a wide range of biological processes, they were selected to examine whether combining them would be more effective to modulate mitochondrial function. In HUVEC cells our results demonstrate that the co-administration of these natural products increased mitochondrial mass and mitochondrial DNA content. Additionally, combined use of both compounds increased SIRT1 enzymatic activity and induced mitochondrial biogenesis factors such as PGC1-α, TFAM and NRF-1. Therefore, identification of this novel synergism may provide a new perspective for future treatments aiming to modulate the mitochondrial activity with implications in maintaining endothelial function which is crucial in the regulation of immune response. Further studies to discover the molecular details of this crosstalk and to identify new combinations of active compounds affecting the mitochondrial function will be extremely beneficial to prevent mitochondrial decline.Entities:
Year: 2013 PMID: 23842073 PMCID: PMC3750512 DOI: 10.1186/1742-4933-10-28
Source DB: PubMed Journal: Immun Ageing ISSN: 1742-4933 Impact factor: 6.400
Figure 1The combined treatment of resveratrol and equol strongly increased the number of mitochondria in HUVEC cells. (A) Mitotracker fluorescent intensities were analysed to assess the mitochondrial biogenesis. (B) Relative mitochondrial DNA (mtDNA) content was estimated by qRT-PCR. Representative data of at least 3 experiments each performed in triplicate. (*= P < 0.05, **= P < 0.01). C: control; E: equol; R: resveratrol; E+R: equol + resveratrol.
Figure 2Increase of SIRT1 enzymatic activity by combined administration of resveratrol and equol. Fluorimetric SIRT1 activity assay to determine the effect achieved in HUVEC by the combined exposure to equol and resveratrol. Representative data of at least 3 experiments each performed in triplicate. (*= P < 0.05, **= P < 0.01). AFU: arbitrary fluorescence units; C: control; E: equol; R: resveratrol; E+R: equol + resveratrol.
Figure 3Effect of resveratrol and equol on mRNA expression of PGC1-α (A), NRF-1 (B), TFAM (C) in HUVEC. qRT-PCR measurement to assess the mRNA expression of the mitochondrial biogenesis factors. Representative data of at least 3 experiments each performed in triplicate. (*= P < 0.05, **= P < 0.01). C: control; E: equol; R: resveratrol; E+R: equol + resveratrol.